1887
Volume 2014, Issue 3
  • ISSN: 2305-7823
  • E-ISSN:

There is no abstract available for this article.

Loading

Article metrics loading...

/content/journals/10.5339/gcsp.2014.41
2014-12-01
2019-08-20
Loading full text...

Full text loading...

/deliver/fulltext/gcsp/2014/3/gcsp.2014.41.html?itemId=/content/journals/10.5339/gcsp.2014.41&mimeType=html&fmt=ahah

References

  1. [1]. Kaba   RA., , Camm   AJ., , Williams   TM., , Sharma   R. . Managing atrial fibrillation in the global community: The European perspective. . Glob Cardiol Sci Pract . 2013; ;2013: 2 : 173– 184 . doi:10.5339/gcsp.2013.24 .
    [Google Scholar]
  2. [2]. Al-Kindi   S. . Lack of reversibility for NOACs. . Glob Cardiol Sci Pract . 2014; ;2014: 1 : 1 . doi:10.5339/gcsp.2014.1 .
    [Google Scholar]
  3. [3]. Kaba   RA., , Ahmed   O., , Cannie   D. . Response to “Lack of reversibility for NOACs.”. . Glob Cardiol Sci Pract . 2014; ;2014: 1 : 2 . doi:10.5339/gcsp.2014.2 .
    [Google Scholar]
  4. [4]. Boehringer Ingelheim. Dabigatran etexilate recommended for approval in atrial fibrillation for stroke prevention in Europe http://www.boehringer-ingelheim.ca/en/news/press_releases/2011/15_april_2011.html .
  5. [5]. Charlton   B., , Redberg   R. . The trouble with dabigatran. . BMJ . 2014 Jul 23; ;349: : g4681 . doi: 10.1136/bmj.g4681 .
    [Google Scholar]
  6. [6]. Connolly   SJ., , Ezekowitz   MD., , Yusuf   S., , Eikelboom   J., , Oldgren   J., , Parekh   A., , Pogue   J., , Reilly   PA., , Themeles   E., , Varrone   J., , Wang   S., , Alings   M., , Xavier   D., , Zhu   J., , Diaz   R., , Lewis   BS., , Darius   H., , Diener   H-C., , Joyner   CD., , Wallentin   L., , RE-LY Steering Committee and Investigators. . Dabigatran versus warfarin in patients with atrial fibrillation. . N Engl J Med . 2009; ;361: 12 : 1139– 1151 . doi:10.1056/NEJMoa0905561 .
    [Google Scholar]
  7. [7]. Cohen   D. . Concerns over data in key dabigatran trial. . BMJ . 2014 Jul 23; ;349: : g4747 . doi: 10.1136/bmj.g4747 .
    [Google Scholar]
  8. [8]. DiNicolantonio   JJ. . Dabigatran or warfarin for the prevention of stroke in atrial fibrillation? A closer look at the RE-LY trial. . Expert Opin Pharmacother . 2012; ;13: 8 : 1101– 1111 . doi: 10.1517/14656566.2012.671809 .
    [Google Scholar]
  9. [9]. Moore   TJ., , Cohen   MR., , Mattison   DR. . Dabigatran, bleeding, and the regulators. . BMJ . 2014 Jul 23; ;349: : g4517 . doi: 10.1136/bmj.g4517 .
    [Google Scholar]
  10. [10]. Boehringer Ingelheim. (2013 September). Boehringer Ingelheim Pharmaceuticals, Inc. Statement on RE-ALIGN Data .
  11. [11]. McConeghy   K., , Bress   A., , Wing   C. . Reports of bleeding-related fatalities with dabigatran and warfarin: An analysis using the food and drug administration adverse events reporting system. . J Am Coll Cardiol . 2013; ;61: 10_S . doi:10.1016/S0735-1097(13)60319-8 .
    [Google Scholar]
  12. [12]. Southworth   MR., , Reichman   ME., , Unger   EF. . Dabigatran and postmarketing reports of bleeding. . N Engl J Med . 2013; ;368: 14 : 1272– 1274 . doi:10.1056/NEJMp1302834 .
    [Google Scholar]
  13. [13]. Bloomberg News. (2013 11-December). Boehringer to Pay $931,000 Fine Over Lost Pradaxa Files .
  14. [14]. Cohen   D. . Dabigatran: How the drug company withheld important analyses. . BMJ . 2014 Jul 23; ;349: : g4670 . doi:10.1136/bmj.g4670 .
    [Google Scholar]
  15. [15]. Boehringer Ingelheim. (2014 25-July). Pradaxa® (dabigatran etexilate): Response to the recent media articles .
  16. [16]. Boehringer Ingelheim. (2014 28-May). Boehringer Ingelheim announces comprehensive settlement of U.S. Pradaxa® (dabigatran etexilate) litigation .
  17. [17]. Boehringer Ingheim. (2014 14-August). Dabigatran and the monitoring of plasma levels in patients .
  18. [18]. Reuters. (2014 25-April). UPDATE 1-Boehringer 2013 profit up on Pradaxa sales, cost cuts .
http://instance.metastore.ingenta.com/content/journals/10.5339/gcsp.2014.41
Loading
  • Article Type: Other
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error